- Home
- LFVN vs ARMP Comparison
LFVN vs ARMP Comparison
Compare LFVN & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFVN | ARMP |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.2M | 125.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LFVN | ARMP |
|---|---|---|
| Price | $5.86 | $6.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 208.0K | 51.8K |
| Earning Date | 02-04-2026 | 11-12-2025 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | ★ 143.91 | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $228,877,000.00 | $5,054,000.00 |
| Revenue This Year | $1.54 | $4.48 |
| Revenue Next Year | $7.00 | N/A |
| P/E Ratio | $7.52 | ★ N/A |
| Revenue Growth | ★ 16.77 | N/A |
| 52 Week Low | $5.47 | $0.90 |
| 52 Week High | $24.73 | $16.34 |
Technical Indicators
Market Signals| Indicator | LFVN | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 42.35 | 53.43 |
| Support Level | $5.50 | $5.75 |
| Resistance Level | $6.17 | $6.37 |
| Average True Range (ATR) | 0.40 | 0.75 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 28.15 | 40.83 |
Price Performance
Historical ComparisonAbout LFVN Lifevantage Corporation (Delaware)
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.